Protective Efficacy and Immunogenicity of a Combinatory DNA Vaccine against Influenza A Virus and the Respiratory Syncytial Virus

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Stab, Viktoria ^a   Nitsche, Sandra ^a   Niezold, Thomas ^a   Storcksdieck genannt Bonsmann, Michael ^a   Wiechers, Andrea ^a   Tippler, Bettina ^a   Hannaman, Drew ^b   Ehrhardt, Christina ^c   Überla, Klaus ^a   Grunwald, Thomas ^a   Tenbusch, Matthias ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Ichor Medical Systems Inc   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; F PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A; LUNG PARENCHYMA; MOUSE; NONHUMAN; PLASMID; PROTECTION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ANIMALS; ANTIGENS, VIRAL; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INFLUENZA A VIRUS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, COMBINED; VACCINES, DNA;

EID: 84881517105     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072217     Document Type: Article

References (41)

1. Bridges C, Thompson W, Meltzer M, (2000) Effectiveness and cost-benefit of influenza vaccination of healthy working adults. JAMA 284: 12-18.
2. Ledgerwood JE, Graham BS, (2009) DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. Human Vaccines 5: 623-626.
3. Ternette N, Tippler B, Uberla K, Grunwald T, (2007) Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 25: 7271-7279 doi:10.1016/j.vaccine.2007.07.025.
4. Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, et al. (1998) Protection against respiratory syncytial virus infection by DNA immunization. The Journal of experimental medicine 188: 681-688.
5. Tenbusch M, Grunwald T, Niezold T, Storcksdieck genannt Bonsmann M, Hannaman D, et al. (2010) Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine 28: 3273-3277 doi:10.1016/j.vaccine.2010.02.090.
6. Kutzler M a, Weiner DB, (2008) DNA vaccines: ready for prime time? Nature reviews Genetics 9: 776-788 doi:10.1038/nrg2432.
7. Ferraro B, Morrow M, Hutnick N, (2011) Clinical applications of DNA vaccines: current progress. Clinical Infectious Diseases 53: 296-302 doi:10.1093/cid/cir334.
8. Frey S, Dagan R, Ashur Y, Chen XQ, Ibarra J, et al. (1999) Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. The Journal of infectious diseases 180: 2018-2022 doi:10.1086/315119.
9. Wiesener N, Schütze T, Lapp S, Lehmann M, Jarasch-Althof N, et al. (2011) Analysis of different DNA vaccines for protection of experimental influenza A virus infection. Viral immunology 24: 321-330 doi:10.1089/vim.2011.0001.
10. Xu K, Ling Z-Y, Sun L, Xu Y, Bian C, et al. (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral immunology 24: 45-56 doi:10.1089/vim.2010.0056.
11. Talaat AM, Lyons R, Johnston S, (2001) A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses. Vaccine 20: 538-544.
12. Albrecht MT, Livingston BD, Pesce JT, Bell MG, Hannaman D, et al. (2012) Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague. Vaccine 30: 4872-4883 doi:10.1016/j.vaccine.2012.04.078.
13. Patel A, Gray M, Li Y, Kobasa D, Yao X, et al. (2012) Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection. Vaccine 30: 626-636 doi:10.1016/j.vaccine.2011.11.017.
14. Ternette N, Stefanou D, Kuate S, Uberla K, (2007) Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J 4: 51 doi:10.1186/1743-422X-4-51.
15. Park SH, Cheong C, Idoyaga J, Kim JY, Choi J-H, et al. (2008) Generation and application of new rat monoclonal antibodies against synthetic FLAG and OLLAS tags for improved immunodetection. Journal of immunological methods 331: 27-38 doi:10.1016/j.jim.2007.10.012.
16. Aricescu AR, Lu W, Jones EY, (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. Acta crystallographica Section D, Biological crystallography 62: 1243-1250 doi:10.1107/S0907444906029799.
17. Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, et al. (2008) Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC immunology 9: 13 doi:10.1186/1471-2172-9-13.
18. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D, (2010) Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28: 1056-1061 doi:10.1016/j.vaccine.2009.10.111.
19. Potthoff A, Schwannecke S, Nabi G, Hoffmann D, Grunwald T, et al. (2009) Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine 27: 2768-2774 doi:10.1016/j.vaccine.2009.03.001.
20. Fouchier RA, Bestebroer TM, Herfst S, Van Der Kemp L, Rimmelzwaan GF, et al. (2000) Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. Journal of clinical microbiology 38: 4096-4101.
21. Yewdell JW, Bennink JR, (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annual review of immunology 17: 51-88 doi:10.1146/annurev.immunol.17.1.51.
22. Chen W, Antón LC, Bennink JR, Yewdell JW, (2000) Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12: 83-93.
23. Mok H, Lee S, Wright DW, Crowe JE, (2008) Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Vaccine 26: 4775-4782 doi:10.1016/j.vaccine.2008.07.012.
24. Kurt-Jones E, Popova L, Kwinn L, Haynes LM, Jones LP, et al. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature immunology 1: 398-401 doi:10.1038/80833.
25. Dabbagh K, Dahl ME, Stepick-Biek P, Lewis DB, (2002) Toll-like receptor 4 is required for optimal development of Th2 immune responses: role of dendritic cells. Journal of immunology (Baltimore, Md: 1950) 168: 4524-4530.
26. Perrin-Cocon L, Agaugué S, Diaz O, Vanbervliet B, Dollet S, et al. (2008) Th1 disabled function in response to TLR4 stimulation of monocyte-derived DC from patients chronically-infected by hepatitis C virus. PloS one 3: e2260 doi:10.1371/journal.pone.0002260.
27. Schlender J, Walliser G, Fricke J, Conzelmann K-K, (2002) Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. Journal of virology 76: 1163-1170 doi:10.1128/JVI.76.3.1163-1170.2002.
28. Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, et al. (2001) Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. Journal of immunology (Baltimore, Md: 1950) 166: 7437-7445.
29. Lo C-Y, Wu Z, Misplon JA, Price GE, Pappas C, et al. (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26: 2062-2072 doi:10.1016/j.vaccine.2008.02.047.
30. Weinfurter JT, Brunner K, Capuano S V, Li C, Broman KW, et al. (2011) Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS pathogens 7: e1002381 doi:10.1371/journal.ppat.1002381.
31. Schotsaert M, Ibañez LI, Fiers W, Saelens X, (2010) Controlling influenza by cytotoxic T-cells: calling for help from destroyers. Journal of biomedicine & biotechnology 2010: 863985 doi:10.1155/2010/863985.
32. Graham BS, Bunton LA, Wright PF, Karzon DT, (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. The Journal of clinical investigation 88: 1026-1033 doi:10.1172/JCI115362.
33. Ostler T, Davidson W, Ehl S, (2002) Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma. European journal of immunology 32: 2117-2123 doi:;10.1002/1521-4141(200208)32:8<2117::AID-IMMU2117>3.0.CO;2-C.
34. De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, et al. (2013) Recombinant influenza virus carrying the RSV F85-93 CTL epitope reduces respiratory syncytial virus replication in mice. Journal of virology. doi:10.1128/JVI.03019-12.
35. Frankild S, De Boer RJ, Lund O, Nielsen M, Kesmir C, (2008) Amino acid similarity accounts for T cell cross-reactivity and for "holes" in the T cell repertoire. PloS one 3: e1831 doi:10.1371/journal.pone.0001831.
36. Zhou Y, Fang F, Chen J, Wang H, Chang H, et al. (2008) Electroporation at low voltages enables DNA vaccine to provide protection against a lethal H5N1 avian influenza virus challenge in mice. Intervirology 51: 241-246 doi:10.1159/000156483.
37. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, et al. (2009) Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. Journal of virology 83: 12601-12610 doi:10.1128/JVI.01036-09.
38. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, et al. (1993) Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. Journal of immunology (Baltimore, Md: 1950) 151: 2032-2040.
39. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, et al. (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. Journal of virology 68: 5321-5325.
40. Kreijtz JHCM, Fouchier R a M, Rimmelzwaan GF, (2011) Immune responses to influenza virus infection. Virus research 162: 19-30 doi:10.1016/j.virusres.2011.09.022.
41. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, et al. (2000) Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. The Journal of infectious diseases 181: 1133-1137 doi:10.1086/315323.